EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Clinicopathological Factors Predicting Pathological Complete Response to Neoadjuvant Anti-HER2 Therapy in HER2-Positive Breast Cancer

Youn Joo Jung, Seungju Lee, Seok Kyeong Kang, Jee Yeon Kim, Ki Seok Choo, Kyung Jin Nam, Ji Hyeon Joo, Jae Joon Kim, Hyun Yul Kim

Oncology · 09.09.2024 · 1-9

DOI: 10.1159/000541019 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology, online erschienen am 09.09.2024. Verfasst von Youn Joo Jung und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Pusan Nat…. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Human epidermal growth factor receptor 2 (HER2)-targeted therapies have shown effectiveness against HER2-positive breast cancer. This makes neoadjuvant chemotherapy (NAC) a valuable option for treating both early and advanced stages of the disease. The tumor’s response to HER2-targeted NAC provides crucial prognostic information. Additionally, it allows for tailoring adjuvant treatment strategies for HER2+ breast cancer based on pathological responses. This study aimed to investigate the clinicopathological factors that influence tumor response.

Methods

We retrospectively analyzed 122 patients diagnosed with HER2+ breast cancer. These patients received NAC and HER2-directed therapy between January 2018 and December 2022 at the Pusan National University Yangsan Hospital. Following surgery, tumor response was evaluated, categorizing patients into two groups: pathological complete response (pCR) and non-pCR groups. We analyzed data on various factors, including age, NAC regimen, type of breast and axillary surgery, clinical stage (cTNM), historical grade, and preoperative levels of carcinoembryonic antigen, cancer antigen 15-3 (CA 15-3), estrogen receptor (ER), progesterone receptor (PR), HER2, p53, and KI-67.

Results

Out of the 122 patients, 75 achieved pCR, while 47 did not. Most clinicopathological factors showed no significant difference between the pCR and non-pCR groups. However, several factors were associated with a higher pCR rate: normal preoperative CA 15-3 levels (odds ratio [OR]: 3.74, confidence interval [CI]: 1.19–11.72, p = 0.02), preoperative ER positivity (OR: 2.65, CI: 1.25–5.59, p = 0.01), PR negativity (OR: 3.92, CI: 1.82–8.45, p < 0.05), and strong preoperative HER2 immunohistochemistry (IHC) 3+ staining. Multivariate analysis confirmed that PR negativity (OR: 2.8, CI: 1.23–6.42, p = 0.01) and strong preoperative HER2 IHC 3+ staining (OR: 0.18, CI: 0.03–0.84, p = 0.04) were independent predictors of a higher pCR rate.

Conclusions

A pCR after NAC impacts patient prognosis and influences the choice of adjuvant treatment for HER2+ breast cancer. Clinicopathological factors can help predict responses to HER2-targeted NAC. In our study, pre-ER/PR negativity, high pre-HER2 levels, and normal CA 15-3 levels were found to be potential predictors of pCR. These findings may contribute to developing more effective treatment strategies for HER2+ breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesHumansFemaleNeoadjuvant TherapyMiddle AgedRetrospective StudiesAdultAgedPrognosisChemotherapy, AdjuvantBiomarkers, TumorTreatment Outcome

Stichwörter der Autor:innen

Anti-HER2 target treatmentHER2-positive breast cancerNeoadjuvant treatmentPathologic complete response

Substanzen

Erb-b2 Receptor Tyrosine KinasesBiomarkers, TumorERBB2 protein, human

Autor:innen und Institutionen

  • Department of Surgery, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Republic of Korea.
  • Department of Pathology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Republic of Korea.
  • Department of Radiology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Republic of Korea.
  • Department of Radiation Oncology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Republic of Korea.
  • Department of Hematology and Oncology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Republic of Korea.

Zitieren

APA

Jung, Y. J., Lee, S., Kang, S. K., Kim, J. Y., Choo, K. S., Nam, K. J., Joo, J. H., Kim, J. J., & Kim, H. Y. (2024). Clinicopathological Factors Predicting Pathological Complete Response to Neoadjuvant Anti-HER2 Therapy in HER2-Positive Breast Cancer. Oncology, 1-9. https://doi.org/10.1159/000541019

Vancouver

Jung YJ, Lee S, Kang SK, Kim JY, Choo KS, Nam KJ, et al. Clinicopathological Factors Predicting Pathological Complete Response to Neoadjuvant Anti-HER2 Therapy in HER2-Positive Breast Cancer. Oncology. 2024:1-9. doi:10.1159/000541019

BibTeX
@article{Jung2024,
  author = {Jung, Youn Joo and Lee, Seungju and Kang, Seok Kyeong and Kim, Jee Yeon and Choo, Ki Seok and Nam, Kyung Jin and Joo, Ji Hyeon and Kim, Jae Joon and Kim, Hyun Yul},
  title = {Clinicopathological Factors Predicting Pathological Complete Response to Neoadjuvant Anti-HER2 Therapy in HER2-Positive Breast Cancer},
  journal = {Oncology},
  year = {2024},
  pages = {1--9},
  doi = {10.1159/000541019}
}
Kostenlos starten →